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The pulmonary collectins, surfactant proteins A and D (SP-A and SP-D) have been implicated in the regulation of the
innate immune system within the lung. In particular, SP-D appears to have both pro- and anti-inflammatory signaling
functions. At present, the molecular mechanisms involved in switching between these functions remain unclear. SP-D
differs in its quaternary structure from SP-A and the other members of the collectin family, such as C1q, in that it forms
large multimers held together by the N-terminal domain, rather than aligning the triple helix domains in the traditional
‘‘bunch of flowers’’ arrangement. There are two cysteine residues within the hydrophobic N terminus of SP-D that are
critical for multimer assembly and have been proposed to be involved in stabilizing disulfide bonds. Here we show that
these cysteines exist within the reduced state in dodecameric SP-D and form a specific target for S-nitrosylation both in
vitro and by endogenous, pulmonary derived nitric oxide (NO) within a rodent acute lung injury model. S-nitrosylation
is becoming increasingly recognized as an important post-translational modification with signaling consequences. The
formation of S-nitrosothiol (SNO)-SP-D both in vivo and in vitro results in a disruption of SP-D multimers such that
trimers become evident. SNO-SP-D but not SP-D, either dodecameric or trimeric, is chemoattractive for macrophages
and induces p38 MAPK phosphorylation. The signaling capacity of SNO-SP-D appears to be mediated by binding to
calreticulin/CD91. We propose that NO controls the dichotomous nature of this pulmonary collectin and that
posttranslational modification by S-nitrosylation causes quaternary structural alterations in SP-D, causing it to switch
its inflammatory signaling role. This represents new insight into both the regulation of protein function by S-
nitrosylation and NO’s role in innate immunity.
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Introduction
Nitric oxide (NO) has long presented a curious dichotomy
within biologic systems, namely that it is both an important
physiological regulator and the mediator of many pathologies
[1–3]. Nowhere is this more clearly demonstrated than within
the pulmonary system. Whereas NO is required for the
control of lung vessel and airway dilation, immune defense,
and the maintenance of barrier function, it is also a key
mediator of acute lung injury, bronchopulmonary dysplasia,
respiratory distress syndrome, and asthma [4]. The contra-
dictory behavior of NO is highlighted by the successes and
failures of inhaled NO, which has revolutionized the treat-
ment of persistent pulmonary hypertension of the newborn
and, potentially, bronchopulmonary dysplasia [5,6], but has
failed to help—and may even harm—patients with acute
respiratory distress syndrome [7].
The role of NO in signal transduction pathways, other than
its activation of the cyclic-GMP (cGMP) pathway [8,9], has
become of increasing relevance in recent years. Of particular
interest is the capability of NO to induce signaling functions
via the post-translational modiﬁcation of proteins [10–12].
Among these modiﬁcations, S-nitrosylation is emerging as an
important regulator of protein function [13,14]. S-nitro-
sylation is a covalent modiﬁcation of thiol groups by
formation of a thionitrite S-nitrosothiol (SNO) group, and
can occur either through direct reaction, metal catalysis, or
via the formation of higher nitrogen oxides [12]. Over the
past decade, more than a hundred proteins [15] have been
shown to become S-nitrosylated, and in many cases, this
modiﬁcation is accompanied by altered function. The
potential for SNO as a post-translational regulator of protein
function has been highlighted by recent proteomic and
targeted studies [16–18].
In parallel to the dichotomous nature of NO in the lung,
the pulmonary collectin surfactant protein D (SP-D) (Swis-
sprot (http://www.ebi.ac.uk/swissprot/index.html) accession
number P50404) has been shown to be important in
mediating pathogen clearance and the pulmonary inﬂamma-
tory response, whereas animals lacking SP-D develop sponta-
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PLoS BIOLOGYneous inﬂammation within the lung and associated pulmo-
nary disease [19,20]. How the pro- and anti-inﬂammatory
functions of SP-D are regulated is unknown. However, it has
been suggested that pro-inﬂammatory functions are medi-
ated by the tail domains, via binding to CD91 and calreticulin,
and anti-inﬂammatory by the head domains, via binding to
SIRP-1a [21]. SP-D has a fairly complex quaternary structure
in which monomers (43 kDa) are assembled into tetramers of
trimers thus forming dodecamers. Dodecamers may be
further assembled into large multimeric structures (Figure
1A). Different from SP-A, the oligomerization of SP-D results
in the burial of the tail domains while the head domains are
exposed. Oligomerization is dependent upon the cysteine
residues at positions 15 and 20 within the N-terminal tail
region [22]. Mutation of these residues results in SP-D being
incapable of forming any quaternary complex larger than a
trimer [23]. Transgenic animals that are SP-D
–/– and express a
mutant form of SP-D with serine replacing the cysteines at
positions 15 and 20 [24], still demonstrate enlarged and
foamy macrophages within the airways. Furthermore, over-
expression of the mutant protein in SP-D
þ/þ results in the
appearance of activated macrophages in the airspace. These
observations strongly imply that oligomerization of SP-D is
critical to its control of the inﬂammatory response of the
lung.
Cysteines 15 and 20 are located within the most hydro-
phobic region of the SP-D protein (Figure 1B) [22]. The
positioning of a reduced cysteine within such a hydrophobic
region has been proposed as a motif for the formation of a
SNO [13]. We propose that SP-D is a target for NO reactivity
and that such chemistry may alter the oligomeric structure of
SP-D and thus regulate its inﬂammatory function. We
examined the forces involved in maintaining the dodeca-
meric structure of SP-D. Furthermore, we have found that SP-
Di sS-nitrosylated by NO both in vivo and in vitro and that
this modiﬁcation is associated with alterations in quaternary
structure. Furthermore, we show that nitrosylation results in
a functional switch, activating the pro-inﬂammatory capa-
bilities of SP-D. Thus, NO-mediated modiﬁcation may
explain the dichotomous nature of SP-D within innate lung
immunity.
Results
The oligomerization of SP-D into its dodecameric form is
dependent upon the cysteines 15 and 20 in the hydrophobic
tail of the monomer. This has led to the suggestion that the
dodecamer may be held together via a series of disulﬁde
bonds between the cysteines. To investigate this possibility,
we chose to examine the reductive state of these cysteines via
reaction with the alkylating agent N-ethyl maleimide (NEM).
As shown in Figure 2A, we were able to label rat recombinant
SP-D (rSP-D) with NEM linked biotin; however, we were
unable to label rSP-D in which the cysteines 15 and 20 had
been mutated to serine (ser 15/20 SP-D). These data indicate
that within the recombinant protein, these two cysteines exist
Figure 1. SP-D Structure
(A) A model of SP-D structure. (Upper panel) The SP-D monomer (43 kDa)
consists of a carbohydrate recognition domain which forms the globular
head structure. This domain is connected to the collagen-like helical tail
domain by a short, 30–amino acid, neck domain. At the end of the tail
domain is the amino terminus in which cysteines 15 and 20 are
positioned (shown as yellow projections). (Lower panel)S t y l i z e d
representation of SP-D multimer assembly (note tail domains are shown
shortened for ease of visualization). The head and neck domains drive
the aggregation of the SP-D monomer to form a trimer of ;130 kDa.
These trimers associate to form a dodecamer (;520 kDa). The forces
holding this dodecamer together are unclear, although there is a
dependency upon the amino-terminal cysteines as mutant lacking these
cysteines do not form dodecamers. These dodecamers can assemble to a
multimer of greater than 1 MDa. It is unclear whether the dodecamer is
an essential intermediate in multimer formation. It should be noted that
neither the trimer nor the dodecamer are globular proteins, due to the
presence of the long collagen tail and thus under native conditions will
behave as molecules with greater molecular radius.
(B) Hydropathy plot of SP-D. A Kyle Doolittle hydropathy plot for the SP-
D sequence was constructed using a window size of nine residues. A
positive value indicates a region of hydrophobicity. The position of
cysteines 15 and 20 are marked within the tail domain. As one can see,
this is the most hydrophobic portion of the molecule.
doi:10.1371/journal.pbio.0060266.g001
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Author Summary
Cells of the lung lining secrete a microbe-binding molecule called
surfactant protein D (SP-D) that helps activate the inflammatory
system against invading pathogens. In the absence of infection, SP-D
is important in limiting inflammation, demonstrated by the fact that
mice lacking the SP-D gene have chronic inflammation and
emphysema. SP-D has two structural features—a lectin-like head
domain and a collagenous tail domain—that, respectively, inhibit and
stimulate inflammation. Here we define a mechanism for generating
the active ‘‘inflammatory’’ version of SP-D. SP-D is held together in its
multimeric state by interacting cysteine residues, which are suscep-
tibletomodificationbythegaseoussecondmessenger, nitricoxide,to
form S-nitrosothiols. In this multimeric state, the tail domains are
buried, limiting the ability of SP-D to activate inflammation. S-
nitrosylation causes the multimers to fall apart into trimers, exposing
the tail domain. S-nitrosylated SP-D induces inflammatory cell
activation as determined by chemotaxis, calcium influx, and phos-
phorylation state. This activity is dependent upon both the S-
nitrosothiol and the disruption of SP-D’s multimeric structure. These
modifications are observed in an in vivo model of inflammation and
form a critical part of the process. A model is proposed in which nitric
oxide operates as a molecular switch for SP-D.at least partially within a reduced state, but that the other
cysteines located in the head domain are oxidized. Examina-
tion of these two proteins by SDS-PAGE further demon-
strates the nature and importance of these cysteines (Figure
2B). With rSP-D, SDS-PAGE in the absence of thiol reductants
results in a single band at the molecular size equivalent to a
trimer. Treatment with either dithiothreitol or b-mercapto-
ethanol reduced rSP-D to a monomer. Interestingly ser15/20
SP-D was a monomer in SDS-PAGE analysis irrespective of
thiol reduction. These data indicate that these two cysteines
are critical in SP-D structure and that disulﬁde bonds
involving them are critical in the trimeric structure but not
in the dodecamer. Indeed, few inter-trimeric disulﬁde bonds
exist in rSP-D, as shown by the single predominant band seen
in nonreducing electrophoresis.
One of the proposed motifs for the formation of SNO is
the presence of a cysteine residue within a hydrophobic
pocket of protein structure [18,25]. Having established that
these two cysteines were critically important to the dodeca-
meric structure of SP-D and that this is not through the
formation of disulﬁde bonds, we investigated whether they
were targets for S-nitrosylation. We examined both bron-
choalveolar lavage (BAL) and rSP-D following transnitrosa-
tion with S-nitrosocysteine (SNOC) (Figure 3A and 3B). As
evidenced by the biotin-switch assay [16], SP-D, both within
BAL and in recombinant form, was readily S-nitrosylated by
SNOC. Analysis of BAL by native electrophoresis demon-
strates that the multimeric/dodecameric forms are so large
that they can barely enter the gel. However, following in vitro
S-nitrosylation of BAL from mice overexpressing SP-D or
rSP-D, the size of the SP-D complex is reduced such that
lower molecular weight forms are visible (Figure 3A). In
parallel, we analyzed BAL from mice overexpressing SP-D by
gel ﬁltration revealing (Figure 3B) that native SP-D exists in a
complex  1 MDa in size (corresponding to the either the
dodecamer or higher-order multimers, Figure 1A). Treatment
of this BAL with SNOC reduces the complex size to below 720
kDa (corresponding to the trimer, Figure 1A). Lower–
molecular weight SP-D (;120 and 50 kDa, monomer and
potentially dimer, respectively) is visible with and without
SNOC treatment. Further native electrophoresis of the gel
ﬁltration fractions reveals that the .1-MDa fraction does
consist of complexes that are too large to enter the gel, such
as multimers and dodecamers [26,27], while the trimers are
found in the 720-kDa fraction. The lower two fractions
contain smaller forms of SP-D which may be an artifact
resulting from the use of overexpressing mice. In summary, it
appears that in vitro transnitrosation results in the formation
of SNO-SP-D and alters the quaternary structure of SP-D
such that its multimeric size is reduced.
Previously it has been suggested, in particular for SP-A,
that differential binding of the head and tail regions of the
collectins by receptors on macrophages may control their
anti- and pro-inﬂammatory functions [21,27]. In the struc-
tural model of SP-D (Figure 1A), it is proposed that within the
multimer, the tail domains are buried and the head domains
exposed; however, disruption of this structure, such as that
shown with SNOC treatment (Figure 3), leads to exposure of
the tail region. Therefore, it is reasonable to suggest that
disruption of the multimeric structure by S-nitrosylation
would lead to activation of those functions of SP-D mediated
by the tail domain of the protein. We examined the ability of
both modiﬁed and unmodiﬁed SP-D to act as a chemo-
attractant for macrophages. By using a modiﬁed Boyden
chamber with RAW 264.7 cells as the target, BAL and rSP-D,
both before and after treatment with SNOC, were assessed
for their ability to induce chemotaxis (Figure 4). Both SNO-
BAL and SNO-SP-D induced signiﬁcantly greater RAW cell
chemotaxis than their respective controls; furthermore, there
was clearly a dose dependence to this induction (Figure 4A
and 4B). This chemoattractant function of SNO-SP-D did not
result from NO release and activation of guanylate cyclase,
because the classical inhibitor ODQ, did not reduce the effect
of SNO-SP-D (unpublished data). Because there are multiple
potential cysteine containing proteins within BAL that could
be transnitrosated by SNOC, one cannot from these data
infer that the effect within BAL depends on the formation of
SNO-SP-D. Therefore, the effect of SP-D immunoprecipita-
tion upon SNO-BAL–induced chemotaxis was examined.
Removal of SNO-SP-D from SNOC treated BAL ablates the
chemotactic response mediated by this treatment (Figure 4C).
The importance of SP-D in mediating the effects of SNO
treatment upon chemotaxis was demonstrated by examining
BAL from SP-D
–/– mice. SNOC-treatment of SP-D
–/– BAL
failed to elicit an in increase in RAW cell chemotaxis (Figure
4D). Collectively, these data demonstrate that SNO-SP-D is
responsible for the induction of macrophage chemotaxis
following in vitro SNOC treatment.
SNOC treatment alters the quaternary structure of SP-D
Figure 2. Role of Cysteine Residues 15 and 20 in Formation of SP-D
Trimers
(A) Recombinant rat SP-D (RrSP-D) or a mutant in which cysteines 15 and
20 have been mutated to serine (Ser15/20) were denatured under
reducing (using mercaptoehtanol or dithiothreitol as the reductant) and
non-reducing conditions. The resultant proteins were analyzed by SDS-
PAGE and Western blotting with SP-D antibody.
(B) RrSP-D and Ser15/20 were pre-incubated with NEM-linked to biotin at
37 8C for half an hour either with or without prior incubation with
unlinked NEM. Biotin-labeling was determined by Western blotting
following SDS-PAGE with anti-biotin antibody.
doi:10.1371/journal.pbio.0060266.g002
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Role of SNO-SP-D in InflammationFigure 4. SNO-SP-D Induces Macrophage Chemotaxis
(A and B) BAL and recombinant SP-D were assessed for their ability to induce RAW 264.7 macrophage migration using a modified Boydin chamber,
following treatment with 200 lM SNOC or cysteine.
(C) Using a BAL does of 100 lg/ml, cell migration was assayed subsequent to treatment with anti-SP-D or non-immune IgG.
(D) SNOC treatment of BAL from SP-D
–/– mice did not induce macrophage chemotaxis. (asterisk represents significantly different from BAL; pound
symbol represents significantly different from control or IgG; carat symbol represents significantly different from SNO SP-D
þ/þ; p , 0.05)
doi:10.1371/journal.pbio.0060266.g004
Figure 3. SNO-SP-D Formation In Vitro and Its Effect on Multimerization
(A) (Top) SNO-SP-D formation in BAL. BAL from normal rats either with or without treatment with L-SNOC (200 lM) was analyzed for SNO-SP-D content
by biotin-switch assay. Total SP-D content was also measured by immunoblot. (Middle) Transnitrosation of recombinant SP-D. Control and SNOC treated
recombinant SP-D (0.2 lM) were analyzed by biotin-wwitch assay. W/o biotin-HPDP represents the assay performed in the absence of biotin linked [N-
(6-biotinamido)hexyl-19-(2’ pyridyldithio) propionamide]. (Bottom) Recombinant SP-D (0.2 lM) was transnitrosated with increasing doses of L-SNOC or
exposed to 200 lM authentic NO and then analyzed by biotin-switch assay.
(B) SNOC treatment alters the conformational state of SP-D. (Left panel) BAL from SP-D overexpressing mice or 0.2 lM recombinant SP-D were treated
with L-SNOC and subjected to native electrophoresis and Western blot for SP-D, revealing disruption of the native multimers to dodecamers and
trimers. (Upper right panel) The BAL samples in the left panel were subjected to gel-filtration. Total protein from BAL (0.75 mg) in a volume of 250 ll was
resolved onto a Superdex 200 HR 10/30 column (GE Healthcare Bio-Sciences) for size-exclusion chromatography (SEC) analysis. Protein extracts were
resolved at flow rate of 0.3 ml/min in 25 mM HEPES, PH 7.25, and 150 mM NaCl using an Agilent 1100 Series HLC system. Fractions (0.5 ml) were
collected and concentrated with 5000 NMWL Ultrafree-MC filters (Millipore). The gel filtration column was calibrated using the following mixture of
globular proteins standards: thyroglobulin (669 kDa), ferritin (440 kDa), catalase (232 kDa), aldlase (158 kDa), albumin (67kDa), ovalbumin (43 kDa),
chymotrypsin (25 kDa), and ribonuclease A (13.7 kDa). The void volume was determined from the elution migration of blue dextran (2,000 kDa). The
fractions were analyzed by SDS-PAGE and Western blot for total SP-D content. The large multimers seen in control BAL are reduced in size upon SNOC
treatment. (Lower right panel) Gel filtration samples containing SP-D were analyzed by native electrophoresis and Western blot, revealing that the 720-
kDa fraction that arises upon SNOC treatment contains dodecamers and trimers of SP-D.
doi:10.1371/journal.pbio.0060266.g003
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Role of SNO-SP-D in Inflammationand results in the production of SNO-SP-D. NEM is only
capable of alkylating residues 15 and/or 20 (Figure 2)
suggesting that one or both of these residues would be the
target for transnitrosation by SNOC. To conﬁrm this
supposition, we examined the ability of SNOC to trans-
nitrosate both rSP-D and ser 15/20 SP-D (Figure 5A). rSP-D
but not ser 15/20 SP-D was effectively nitrosated by SNOC as
determined by the biotin-switch assay. In conjunction with
these assays, the ability of the treated SP-D molecules to
induce macrophage chemotaxis was also measured. SNO-rSP-
D was found to be a potent inducer of chemotaxis, however,
neither cysteine-treated rSP-D nor ser 15/20 SP-D had a
signiﬁcant effect (Figure 5B). This is despite the fact that
within these molecules, the tail region is exposed, implying
that nitrosation not only results in structural disruption but
is also critical to the signaling function within macrophages.
Having shown that SP-D is a target for transnitrosation and
that SNO-SP-D formed in this way has potential functional
consequences, it remained to be demonstrated that this
modiﬁcation occurred in vivo. Previously, we used intra-
tracheal administration of bleomycin as a model of acute lung
injury within both rats and mice [28–30]. In rats, the peak
inﬂammatory response is observed 7 d after injury. This
inﬂammatory response resolves by day 14 and resultant
ﬁbrosis occurs around day 21. Within mice, this timeline is
slightly extended with the inﬂammatory response extending
out beyond 14 d. We examined the BAL ﬂuid from control,
saline-treated, and bleomycin-treated rats and mice for
evidence of SP-D nitrosylation over the 21 d following
treatment. In control and saline-treated rats, SNO-SP-D was
either undetected or seen in marginal quantities; however,
SNO-SP-D was readily detected following bleomycin-treat-
ment peaking at day 2 and day 4 after bleomycin injury
(Figure 6A). Therefore, SNO-SP-D formation precedes the
peak inﬂammatory response, suggesting that nitrosylation
may be an early event. Similar results were obtained in BAL
samples from mice where SNO-SP-D was detected 8 d after
bleomycin treatment but not in control or saline-treated
animals (Figure 6B). To determine whether the quaternary
structure of SP-D was altered with injury, we examined SP-D
from injured and control rats at day 4 by Western blot
following native and reducing gel electrophoresis. In native
gels of control samples, none of the lower–molecular weight
forms of SP-D was observed (Figure 6C). However, BAL from
injured rats, examined in the same manner, clearly demon-
strated lower–molecular weight forms of SP-D (Figure 6C).
The presence of a small amount of lower–molecular weight
SP-D in the saline-treated animals is not surprising, because
this treatment has been shown to be injurious and elicit a
slight inﬂammatory response [28]. These observations show
that SNO-SP-D is formed both in vivo as well as in vitro and
that this formation is associated with an altered conforma-
tional state for SP-D.
To demonstrate the dependence of SNO-SP-D formation
upon NOS-generated NO within this in vivo model, we
examined SNO-SP-D generation in iNOS
–/– mice. Previously,
it has been demonstrated that inhibition of iNOS function,
either by genetic or pharmacological means, results in a
degree of resistance to bleomycin injury [31]. In addition SP-
D has been shown to play a critical role in bleomycin induced
acute lung injury [30]. We examined the BAL of both wild-
type and iNOS
–/– mice 8 d after bleomycin injury (Figure 6D).
SNO-SP-D formation was reduced by over 80% in iNOS
–/–
mice relative to wild-type animals following injury. It is
interesting that in both strains, SNO-SP-D formation was
observed, suggesting that NO production is still increased
within the iNOS
–/– mice in this acute injury model.
The functional effects of SNO-SP-D within this model were
examined by using the chemotaxis assay. As predicted, BAL
from bleomycin-treated rats promoted signiﬁcantly greater
chemotaxis than that from saline-treated animals (Figure 7).
Pretreatment of the BAL with ascorbate, which removes the
NO moiety from SNO (Figure7A, inset), signiﬁcantly reduced
the chemotactic efﬁcacy of BAL from bleomycin treated rats
(Figure 7A). There was no effect of this treatment upon BAL-
Figure 5. Chemotactic Activity of SNO-SP-D Trimers
(A) Recombinant rat SP-D (RrSP-D) or the mutant (Ser15/20) was
incubated with 200 lM L-cysteine or L-CysNO for 30 min at room
temperature. SNO content was analyzed by Western blotting of non-
reduced SDS-PAGE samples following use of the biotin switch assay.
(B) Chemotactic activity recombinant and modified SP-Ds. 0.1 lg/ml of
the treated SP-Ds in (A) were used to measure chemotaxis in a modified
Boyden chamber assay with RAW 264.7 cells. Data are mean 6 SEM.
(asterisk represents significantly different from RrSP-D; p , 0.05)
doi:10.1371/journal.pbio.0060266.g005
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Role of SNO-SP-D in Inflammationinduced chemotaxis from saline treated rats. To conﬁrm the
importance of SP-D in the SNO-mediated increase, the
chemotaxis assay was repeated using BAL that had been
pre-immunoprecipitated with either antibodies to SP-D or
non-immune IgG (Figure 7B). Neither antibody treatment
had an effect on chemotaxis induced by BAL from saline-
treated rats. However, anti-SP-D treatment produced a
signiﬁcant reduction in chemotaxis induced by BAL from
bleomycin-treated rats, conﬁrming the requirement for SP-D
in the SNO-mediated effect. A word of caution is worthy, as
one cannot conﬁrm the effects of SP-D immunoprecipitation
upon other chemotactic factors, such as cytokines, in these
experiments; and thus the entire reduction observed may not
result from SP-D removal. Although it is of note that non-
immune IgG had no effect. These results conﬁrm our in vitro
observations in an in vivo model, namely that SP-D is
nitrosylated, reduced in multimeric size, and becomes a
pro-inﬂammatory signal.
The observation of SNO-SP-D–mediated chemotaxis shows
that there is a functional effect of nitrosylation but does not
provide a mechanism for this effect. One of the main events
that occurs during the induction of chemotaxis within a
macrophage is the inﬂux of extracellular calcium. To examine
whether SNO-SP-D had an effect on intracellular calcium
levels, RAW cells were loaded with the calcium responsive
ﬂuorescent dye, Fura-2. Control BAL had little effect upon
the intracellular calcium concentration (Figure 8A), as there
was no increase in ﬂuorescence upon addition. However,
SNO-BAL resulted in a signiﬁcant calcium inﬂux with a peak
response approximately 2 min after its addition to the
medium. Similar results were obtained with rSP-D, although
the time constant of induction was much lower, as by 100 s,
intracellular calcium levels had returned to normal. In
addition to inducing chemotaxis, a predicted downstream
consequence of such a calcium inﬂux is the phosphorylation
and activation of p38 MAPK. Figure 8B shows that SNO-BAL
from wild-type mice, but not control BAL or SNO-BAL from
SP-D
–/– mice, was capable of inducing phosphorylation of p38
MAPK. These data establish that SNO-SP-D, but not native
SP-D, is capable of inducing inﬂammatory signaling within
macrophages and provides some insight into the mechanism
of this signaling.
Gardai et al. proposed that collectins exert their anti-
inﬂammatory function through SIRP-1a and their inﬂamma-
tory function through calretuclin (CRT)/CD91 [21]. It was
proposed that the pro-inﬂammatory actions of SNO-SP-D,
namely increased chemotaxis and intracellular signaling,
occurred via binding to calreticulin. To investigate this
possibility, the effects of pretreament of RAW cells with
antibodies to CRT or SIRP-1a upon SNO-BAL-mediated
chemotaxis were investigated. Figure 8C demonstrates that
SNO treatment once again induced chemotaxis in RAW cells.
Furthermore, pretreatment of the RAW cells with either non-
immune IgG or anti-SIRP-1a had no effect upon the degree
of chemotaxis in eithe rnormal or SNO-trated BAL. However,
pretreatment with anti-CRT speciﬁcally reduced the SNO-
BAL mediated chemotaxis to the level of untreated BAL.
Pretreatment of RAW cells with anti-CRT resulted in a
minimal increase in p38 phosphorylation (Figure 8D).
However, while anti-CRT treatment had little effect on p38
phosphorylation within BAL-treated cells; it resulted in a
signiﬁcant decrease in SNO-BAL–induced phosphorylation.
Figure 6. Acute Lung Injury in the Rodent Produces Results in SNO-SP-D Formation and Multimer Disruption
(A) Untreated (control), saline, or bleomycin was intratracheally administered to Sprague-Dawley rats. BAL was collected at days 2, 4, 7, 14, and 21 after
injection. BAL (upper) was subjected to biotin-switch assay to detect SNO-SP-D. (Lower) Total SP-D in BAL was identified by immunoblot.
(B) Untreated (control), saline, or bleomycin was intratracheally injected at a dose of 8 U/kg in Sprague-Dawley rats. BAL was collected at day 4 after
injection. BAL (upper) was subjected to electrophoresis for native gel to detect different fragments of SP-D. BAL (middle) was subjected to biotin-switch
assay to detect SNO-SP-D. (Lower) Total SP-D in BAL was identified by immunoblot.
(C) Untreated (control), saline, or bleomycin was administered to C57/BL6 mice intratracheally at a dose of 3 U/kg. BAL was collected at day 8 after
treatment; total SNO content within the BAL was 0.2 6 0.22 lM in control mice and 2.1 6 0.88 lM in bleomycin treated. SNO-SP-D content was
assessed by the biotin switch method.
(D) SNO-SP-D in the BAL of bleomycin-treated wild type versus bleomycin-treated iNOS
–/– mice (8-d post-injury) was measured by biotin-switch assay;
Total input of SP-D was same between groups. (asterisk represents significantly different from wild type; p , 0.05). Representative blots show SNO-SP-D
and total SP-D. Data are mean 6 SEM.
doi:10.1371/journal.pbio.0060266.g006
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Role of SNO-SP-D in InflammationThese results indicate that not only does nitrosylation of BAL,
and hence SP-D, produce increased inﬂammatory signaling,
as demonstrated by increased RAW cell chemotaxis and p38
phosphorylation, but that this activity is mediated by CRT.
Discussion
The results presented here demonstrate that SP-D can be
nitrosylated both in vitro and in vivo. Further, they
demonstrate that this nitrosylation is associated with dis-
ruption of the multimeric structure of native SP-D and that
these modiﬁcations result in a pro-inﬂammatory signaling
activity with macrophages. From these observations, we
propose an extension of the model of Gardai et al. speciﬁcally
for SP-D [21] (Figure 9). Within this model, SP-D exists within
the lung lining ﬂuid in large multimers, such that only the
head domain, the carbohydrate recognition domain, is
exposed. These multimers are capable of interacting either
with invading pathogens or to the cell surface receptor, SIRP-
1a. SP-D binding to SIRP-1a results in suppression of p38
phosphorylation via SHP-1. Thus multimeric/dodecameric
SP-D could reduce inﬂammatory signaling via SHP-1–
mediated inhibition of p38 and reduced activation of NF-
jB. Presumably the interaction of the head domain with
pathogenic molecules, such as lipopolysaccharide (LPS),
results in SP-D subunits, probably trimers, being pulled from
the multimer resulting in tail domain exposure. Exposed tail
domains are then available for interaction with CRT/CD91,
resulting in activation of p38 phosphorylation and potentially
NF-jB and its downstream inﬂammatory consequences. It is
important to note that the data here do not address NF-jB
activation, and this part of the model remains a proposal at
this time.
NO can be produced throughout the lung either from
nNOS, which is present throughout the pulmonary epithe-
lium [32], or from iNOS, whose synthesis is induced in either
pulmonary epithelial cells or alveolar macrophages by pro-
inﬂammatory cytokines [33]. The presence of two reactive
cysteines within the hydrophobic tail domain (Figure 1)
makes SP-D a prime target for NO-mediated post-transla-
tional modiﬁcation, resulting in the formation of SNO-SP-D.
As a consequence of this nitrosylation the multimeric
structure of SP-D is disrupted and trimers are released. The
resulting exposure of the tail domains allows for interaction
with CRT/CD91 and the activation of p38 phosphorylation
and potentially downstream pro-inﬂammatory signaling. In
this way, pro-inﬂammatory signaling of SP-D can be induced
by either the presence of pathogens or chemically via NO
production. Previously it has been demonstrated in hemo-
globin that changes in protein structure can affect the ability
of cysteine residues to be nitrosylated or not [34]. In addition,
the functions of a wide range of proteins—including channel
proteins such as CFTR, G proteins, metabolic enzymes, and
transcription factors—have been shown to be regulated by
SNO formation both in vivo and in vitro [13,35]. However,
although SNO modiﬁcation has been reported to induce
assembly in both dynamin and arginase 1 [36,37], this is the
ﬁrst demonstration, to our knowledge, of a SNO-modiﬁcation
promoting multimeric disassembly and a switch in function,
and thus represents a novel mechanism of action for this
redox-based signal.
Our model provides a mechanistic basis to explain the
apparently dichotomous nature of SP-D as both a pro and
anti-inﬂammatory molecule [19,27,38]. The key to this model
is that it is the exposure of the tail domains that allows for
CRT binding [21]. We have not at this time determined
whether the association of SNO-SP-D with CRT requires the
presence of the NO group or if it is merely the tail domain
exposure that is required. In the later instance, one can see
that other chemical modiﬁcations could also result in pro-
inﬂammatory SP-D signaling. For instance, primary oxidation
of these same cysteine residues would result in sulfenic acid
formation, which can reasonably be predicted to also cause
multimer disassembly. In regard to this question, recombi-
nant SP-D, which is often in the trimeric state, can induce
neutrophil chemotaxis; although it should be noted that in
the studies presented here recombinant SP-D had a minimal
chemotactic effect upon RAW cells. Also the ser 15/20
mutant, in which the tail domains are exposed, does not
induce chemotaxis implying that there is a greater level of
complexity to this signaling.
In the original model of Gardai et al. [21], which was
primarily based upon studies with SP-A, the association of the
collectin with a pathogen was the required step to initiate
CRT binding. It was proposed that the tail domains had a low
afﬁnity for CRT and thus the aggregation of collectin
molecules upon a pathogen was required to provide sufﬁcient
Figure 7. BAL from Bleomycin-Treated Rats Induces Macrophage
Chemotaxis in Part through SNO-SP-D
(A) BAL from bleomycin- and saline-treated rats were analyzed for their
ability to induce RAW cell chemotaxis. Bleomycin BAL induced chemo-
taxis to a greater extent than saline BAL; however, pretreatment with
ascorbate to remove SNO abrogated this response. The effect of
ascorbate treatment on BAL SNO-SP-D content is shown in the inset
where samples were analyzed by biotin-switch.
(B) The importance of SP-D in this SNO-mediated increase is
demonstrated by effect of SP-D immunoprecipitation. Bleomycin and
saline BAL were analyzed for chemotactic effect following pretreatment
with anti-SP-D or non-immune IgG. Only anti-SP-D pre-treatement
reduced the increase in chemotaxis induced following bleomycin
administration. (asterisk represents significantly different from saline-
BAL; # represents significantly different from control or IgG; p , 0.05)
doi:10.1371/journal.pbio.0060266.g007
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Role of SNO-SP-D in Inflammationbinding energy. Within our model, one would predict that
SNO-SP-D is not required to be associated with any other
macromolecule in order to bind CRT, as CRT-mediated
effects can be produced by SNO-SP-D alone (Figure 8).
Therefore, it is implied within this model that the tail domain
of SP-D has a higher afﬁnity for CRT than that of SP-A. This
could result from the presence of the nitrosothiol moiety
upon the modiﬁed SP-D or be simply a feature of the exposed
SP-D tail domain. The precise mechanism of SP-D and CRT
interaction warrants further investigation.
Examination of the BAL samples from the bleomycin-
treated rats and mice (Figure 4) reveals that, although
nitrosylation of SP-D occurs and that there is disruption of
the multimeric structure, much of the SP-D is unaffected.
Therefore, one can safely assume that SP-D is binding to both
SIRP-1a and to CRT, and that the balance of this binding
determines what is the ﬁnal consequence of cellulare
association with SP-D. In other words, SP-D may operate as
an integrator of the status of the lung lining, initiating
inﬂammatory responses under a variety of pathological
conditions, such as infection or nitrosative stress, while
maintaining a quiescent state in the absence of stress. It is
important to note that SP-D is only one of a number of
potential target proteins that can be nitrosylated within the
airway, including channel proteins, G proteins, and tran-
scription factors [35]. This is of particular relevance when one
considers the effects of inhaled NO, whose effects could be
either pro- or anti-inﬂammatory, depending upon the
conditions of its administration and the subject’s lung. For
instance, in our model, SNO-SP-D would initiate a pro-
inﬂammatory response via NF-jB activation; however, SNO
formation on NF-jB itself has been shown to inhibit
activation [39]. Therefore, one can see that the potential
effects of NO inhalation on pulmonary inﬂammation will be
condition dependent.
In summary, the studies outlined here reveal that SP-D
function can be controlled through post-translational mod-
iﬁcation by NO; and this modiﬁcation alters the quaternary
structure of SP-D by disrupting its multimeric state such that
trimers are formed. In addition, the formation of SNO-SP-D
trimers initiates a pro-inﬂammatory response through CRT/
CD91 and p38 activation. This is a novel mechanism of
regulation for both NO and collectins and allows for the
consideration of a novel mode of action for NO.
Materials and Methods
SNO-protein synthesis. In order to generate S-nitrosylated
proteins, BAL (300 lg/ml of total protein) or recombinant rat SP-D
(10 lg/ml) was exposed to L-CysNO (200 lM) in the dark for 30 min at
room temperature. The S-nitrosylated proteins were then puriﬁed on
a G25 Sephadex column (Biorad). The generation of protein S-
nitrosocysteine content was evaluated by reaction with copper/
cysteine coupled with chemiluminescent detection, with S-nitro-
soglutathione as the standard, [40] using a Sievers NOA 280 (GE).
Within BAL, under these conditions 23.7 6 6.91 nmoles of SNO per
mg of protein (mean 6 SD, n¼4) were generated from a basal level of
3.3 6 0.96 nmoles/mg protein (mean 6 SD, n ¼ 4).
Biotin-Switch Assay for Detection of SNO-SP-D. Detection of SNO-SP-D
was performed via an adaptation of the biotin switch method [16].
BAL (30 lg total protein) in HEN buffer (25 mM Hepes, pH 7.7/0.1
mM EDTA/0.01 mM neocuproine),and 20 lM N-ethylmaleimide
(NEM) at 37 8C for 30 min to block free thiols. Excess NEM was
removed by protein precipitation using cold acetone. Protein pellets
were resuspended in HENS buffer (HEN 1% SDS), SNO bonds were
decomposed by adding 20 mM sodium ascorbate. The newly formed
thiols were then linked with the sulhydryl-speciﬁc biotinylating
reagent N-[6-biotinamido)-hexyl]-1-(2-pyridyldithio) propionamide
(Pierce). Biotinylated proteins were precipitated with Streptavidin-
agarose beads and Western blot analysis was performed to detect the
amount of SP-D remaining in the samples.
Western blots. Immunoblotting for SP-D was performed using an
equal protein 5lg of BAL ﬂuid per lane. Samples were loaded on a 4–
Figure 8. SNO-BAL Induces Inflammatory Signaling in RAW Cells via CRT
(A) RAW 264.7 macrophages grown on coverslips were preloaded with fura-2AM and stimulated with BAL (100 lg/ml) or SNO-BAL (100 lg/ml) from SP-
D
þ/þ mice. Change in [Ca2þ]i was record from 50–70 cells.
(B) RAW 264.7 macrophages were treated with BAL or SNO-BAL from either SP-D
þ/þ or SP-D
–/– mice for 5 min. Cell lysates were analyzed for total p38
MAPK and its phosphorylated form (P-p38) by SDS-PAGE and Western blotted with phospho-specific primary antibody.
(C) RAW 264.7 cells were pretreated with 2 lg/ml of anti-SIRP-1a, anti-CRT or an isotype control for 20 min prior to addition to the Boyden chamber.
Treated cells were analyzed for chemotaxis to BAL (control) or SNO-BAL (SNO).
(D) RAW 264.7 cell were pretreated with anti-CRT for 20 min prior to stimulation with BAL or SNO-BAL for an additional 20 min. Cell lysates were then
prepared and analyzed for p38 phosphorylation via SDS PAGE and Western blot with phospho-specific primary antibody. (asterisk represents
significantly different from control; pound symbol represents significantly different from control, IgG, or anti-SIRP-1a (p , 0.05)
doi:10.1371/journal.pbio.0060266.g008
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Role of SNO-SP-D in Inflammation12% precast NuPAGE Bis-Tris polyacrylamide gel (Invitrogen).
Proteins were electrophoresed using MEPS-SDS buffer at 200 V for
35–45 min per the manufacturer’s instructions (Invitrogen). Native
gel electrophoresis was performed using a Novex 4% tris-glycine gel
(Invitrogen). Samples were mixed with a cold native gel sample buffer
(Invitrogen) before loading. Electrophoresis was run at room
temperature at a constant voltage of 80 V for 5 h. Proteins were
then transferred from the gel to a nitrocellulose membrane using the
XCell II Mini-Cell and sandwich blot module (Invitrogen) in Bicine-
10% methanol-0.01% SDS transfer buffer (Invitrogen) at 30 V for 1 h.
Blots were blocked for 1 h at room temperature with 10% nonfat
milk and then incubated with primary SP-D antibody (1:10,000
dilution, The SP-D antibody, a rabbit polyclonal antibody was raised
against puriﬁed rat SP-D as described previously) overnight at 4 8C.
Blots were then incubated with 1:5,000 goat anti-rabbit IgG-horse-
radish peroxidase for 2 h at room temperature. Signal was detected
using the enhanced chemiluminescence kit (Amersham), and blots
were exposed to Kodak Biomax MS ﬁlm.
Model of bleomycin injury. All animals for this study were housed
in the Animal Care Facility of The Children’s Hospital of Phila-
delphia under standard conditions with free access to food and water.
All animal experimental protocols were reviewed and approved by
the Animal Care and Use Committees of both the Children’s Hospital
of Philadelphia and The University of Pennsylvania. Either human
clinical-grade, sterile, and lipopolysaccharide (LPS)-negative saline or
8.0 U/kg of bleomycin sulfate (Bristol Myers Squibb) in 250 ll of saline
was administered intratracheally to 6-wk-old (200–250 g) male
Sprague-Dawley rat littermates (Charles River Breeding Laboratories)
as previously described [29]. Similarly, 8-wk-old C57/B6 mice (25–35
g) were administered with either 50 ll of either LPS-negative saline or
clinical grade, sterile, and LPS-free bleomycin sulfate (3.0 U/kg; Bristo
Myers Squibb) as previously described [30].
Chemotaxis assay. Directed migration (chemotaxis) of cells was
performed as previously described [25] Brieﬂy, 50 llo fc e l l s
suspended at 2 3 10
6 cells/ml in DMEM were placed in the upper
wells of a 48-well microchemotaxis chamber (Neuro Probe). The
lower chambers contained 41 ll of test solution, consisting of DMEM
and either nothing (control); various concentrations of SP-D, SNO-
SP-D, BAL, or SNO-BAL. All test solutions were used in triplicate in
each assay. A polyvinylpyrrolidone-free polycarbonate ﬁlter was
placed between the wells along with the rubber gasket of the
assembly. The ﬁlters used for macrophage chemotaxis had 5-lm
pores (Neuro Probe). The chamber was incubated at 37 8C with 5%
CO2 for 3 h, and then disassembled. Nonmigrating cells were scraped
from the upper surface, and the migrating cells were stained with the
Hemacolor differential blood stain. The ﬁlter was placed on a glass
coverslip and mounted with immersion oil onto a glass slide. Cells
that migrated through the ﬁlter were counted in ten randomly
selected oil-immersion ﬁelds in each well at 1,0003 magniﬁcations.
Data were expressed as cells per oil- immersion ﬁeld for the three
wells used for each solution.
Measurement of [Ca
2þ]i. RAW cells (2 3 10
6) were plated on glass
coverslips (Fisher Scientiﬁc) sized to ﬁt a homeothermic perfusion
chamber platform of an inverted Nikon microscope. The cells were
loaded with 5lM fura-2 acetoxymethylester (Molecular Probes) and
0.2 mg/ml pluronic F-127 (Molecular Probes) in 2 ml HBSS
supplemented with 1% FBS and 1.25 mM CaCl2 for 30 min at 37
8C. The cells were stimulated with HBSS at 37 8C containing BAL or
SNO-BAL and excitation was performed at 334 and 380 nm with two
narrow-bandpass ﬁlters. The emitted ﬂuorescence was ﬁltered (520
nm), captured with a Hamamatso CCD video camera (5123480-pixel
resolution), digitized (256 gray levels), and analyzed with SimplePCI
(Version 3.7.9) software. The amount of Ca
2þ was calculated by
comparing the ratio of ﬂuorescence at each pixel to an in vitro 2-
point calibration curve. The Ca
2þ concentration presented was
obtained by averaging the values of all pixels over a cell body. The
data points were collected at intervals of 5 s.
p38 MAPK analysis. RAW cells (1 3 10
6 cells./ml) were cultured
overnight, then incudbated with Bal or SNO-BAL (100 lg/ml) for 10
min. If anti-caltericulin was used in the experiments, the antibody (2
lg/ml) was added 30 min before the stimulation. Cells were lysed in
lysis buffer [Hepes 20 mM, NaCl 150mM, Glycerol 10%, Triton X100
1%, EGTA 1mM, MgCl2 1.5mM, pH ¼ 7.4] containing protease
inhibitors (PMSF 1mM, NaPyrophosphate 10mM, NaF 50mM, Na
Orthovanadate 2mM, Lactacystin 1lM, AEBSF 1mM, EDTA 0.5mM,
Bestatin 65lM, E-64 0.7lM, Leupeptin 0.5lM, and Aprotinin 0.15lM),
and resolved in 4–10% SDS-PAGE, and blotted to a PVDF membrane
as outlined above. The membranes were probed with a phosphospe-
ciﬁc antibody to p38. To conﬁrm the equal loading, the membranes
were stripped and reprobed for p38.
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